COMPOUNDS AND THEIR USE

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also re...

Full description

Saved in:
Bibliographic Details
Main Authors GRANBERG, Kenneth Lars, BOSTRÖM, Stig Jonas, SAKAMAKI, Shigeki, BERGSTRÖM, Hans Fredrik, FUCHIGAMI, Ryuichi, NIWA, Yasuki, Ulander, Lars Johan Andreas, FUJIO, Masakazu, Bergonzini, Giulia, Graden, Henrik
Format Patent
LanguageEnglish
Published 02.11.2023
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
Bibliography:Application Number: US202318172449